Clinical trial
A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD
NCT00056264 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00056264 |
|---|---|
| Title | A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD |
| Official title | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group, Dose Finding Study Evaluating the Safety and Efficacy of Infliximab Administration in Symptomatic Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease, COPD |
| Intervention type | Drug |
| Interventions | Infliximab |
| Enrollment | 234 |
| Start date | Dec 1, 2002 |
| Completion | Dec 1, 2004 |
| First posted | Mar 10, 2003 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: